Mach7 Technologies Limited

CHIA:M7T Stock Report

Market Cap: AU$88.1m

Mach7 Technologies Valuation

Is M7T undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of M7T when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: M7T (A$0.37) is trading above our estimate of fair value (A$0.14)

Significantly Below Fair Value: M7T is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for M7T?

Key metric: As M7T is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for M7T. This is calculated by dividing M7T's market cap by their current revenue.
What is M7T's PS Ratio?
PS Ratio3x
SalesAU$29.13m
Market CapAU$88.05m

Price to Sales Ratio vs Peers

How does M7T's PS Ratio compare to its peers?

The above table shows the PS ratio for M7T vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average5.2x
ALC Alcidion Group
2.2x8.2%AU$77.9m
CGS Cogstate
2.5x10.9%AU$171.8m
BMT Beamtree Holdings
2.6x21.9%AU$69.5m
ONE Oneview Healthcare
13.4x25.9%AU$209.0m
M7T Mach7 Technologies
3x18.1%AU$88.1m

Price-To-Sales vs Peers: M7T is good value based on its Price-To-Sales Ratio (3x) compared to the peer average (5.1x).

Price to Sales Ratio vs Industry

How does M7T's PS Ratio compare vs other companies in the AU Healthcare Services Industry?

7 CompaniesPrice / SalesEstimated GrowthMarket Cap
MDR MedAdvisor
1.2x13.4%US$105.00m
DOC Doctor Care Anywhere Group
0.3x6.3%US$14.92m
IME ImExHS
0.8x20.5%US$12.02m
VFX Visionflex Group
1.9xn/aUS$8.54m
M7T 3.0xIndustry Avg. 2.9xNo. of Companies7PS0816243240+
7 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: M7T is good value based on its Price-To-Sales Ratio (3x) compared to the Global Healthcare Services industry average (3x).

Price to Sales Ratio vs Fair Ratio

What is M7T's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

M7T PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio3x
Fair PS Ratio0.9x

Price-To-Sales vs Fair Ratio: M7T is expensive based on its Price-To-Sales Ratio (3x) compared to the estimated Fair Price-To-Sales Ratio (0.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst M7T forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentAU$0.37
AU$1.16
+214.3%
14.0%AU$1.36AU$0.95n/a5
Nov ’25AU$0.41
AU$1.16
+180.2%
14.0%AU$1.36AU$0.95n/a5
Oct ’25AU$0.56
AU$1.13
+103.4%
14.6%AU$1.36AU$0.95n/a4
Sep ’25AU$0.54
AU$1.13
+111.0%
14.6%AU$1.36AU$0.95n/a4
Aug ’25AU$0.61
AU$1.23
+99.5%
16.3%AU$1.56AU$1.05n/a4
Jul ’25AU$0.64
AU$1.24
+95.6%
14.6%AU$1.56AU$1.05n/a5
Jun ’25AU$0.66
AU$1.24
+89.6%
14.6%AU$1.56AU$1.05n/a5
May ’25AU$0.72
AU$1.24
+72.5%
14.6%AU$1.56AU$1.05n/a5
Apr ’25AU$0.71
AU$1.24
+74.8%
14.6%AU$1.56AU$1.05n/a5
Mar ’25AU$0.69
AU$1.24
+80.0%
14.5%AU$1.56AU$1.05n/a5
Feb ’25AU$0.71
AU$1.22
+72.2%
15.6%AU$1.56AU$1.05n/a5
Jan ’25AU$0.78
AU$1.23
+57.4%
14.4%AU$1.54AU$1.05n/a5
Dec ’24AU$0.71
AU$1.27
+79.2%
13.4%AU$1.54AU$1.10n/a4
Nov ’24AU$0.70
AU$1.33
+90.0%
12.1%AU$1.54AU$1.15AU$0.413
Oct ’24AU$0.80
AU$1.42
+78.6%
8.5%AU$1.54AU$1.30AU$0.562
Sep ’24AU$0.78
AU$1.42
+82.1%
8.5%AU$1.54AU$1.30AU$0.542
Aug ’24AU$0.86
AU$1.48
+70.5%
11.9%AU$1.65AU$1.30AU$0.612
Jul ’24AU$0.61
AU$1.32
+116.7%
1.7%AU$1.34AU$1.30AU$0.642
Jun ’24AU$0.56
AU$1.32
+137.8%
1.5%AU$1.34AU$1.30AU$0.662
May ’24AU$0.68
AU$1.32
+94.1%
1.5%AU$1.34AU$1.30AU$0.722
Apr ’24AU$0.59
AU$1.27
+113.8%
5.7%AU$1.34AU$1.20AU$0.712
Mar ’24AU$0.61
AU$1.27
+108.5%
5.7%AU$1.34AU$1.20AU$0.692
Feb ’24AU$0.71
AU$1.27
+77.7%
5.5%AU$1.34AU$1.20AU$0.712
Jan ’24AU$0.56
AU$1.27
+127.2%
5.7%AU$1.34AU$1.20AU$0.782
Dec ’23AU$0.58
AU$1.27
+119.4%
5.7%AU$1.34AU$1.20AU$0.712
Nov ’23AU$0.56
AU$1.27
+129.3%
5.7%AU$1.34AU$1.20AU$0.702

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

SDI

AU$122.4m

Engages in the research and development, manufacture, and marketing of dental restorative materials, whitening systems, and other dental materials in Australia, Europe, the United States, and Brazil.

SDI

AU$1.05

7D

5.0%

1Y

26.5%

Doctor Care Anywhere Group

AU$23.1m

Provides digital healthcare and development services in the United Kingdom, Australia, and the Republic of Ireland.

DOC

AU$0.063

7D

-10.0%

1Y

26.0%

SDI

AU$122.4m

Engages in the research and development, manufacture, and marketing of dental restorative materials, whitening systems, and other dental materials in Australia, Europe, the United States, and Brazil.

SDI

AU$1.08

7D

7.0%

1Y

29.5%